UI-2

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameUI-2

Drug Alias Nameanti-NY-ESO-1/HLA-A*0201/HLA-A*0206 TCR T-cell therapy + T-ignite iv vaccine (United Immunity)T-ignitelong peptide antigen (United Immunity)UI-2

ClassificationBiologics > Protein drugs > Recombinant proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyVaccines > Development/production technology > Inactivated vaccine > Subunit vaccine +[6]

Mechanisms of ActionCancer/testis antigen 1 modulatorsHLA Class I Histocompatibility Antigen, A-2 alpha Chain modulators

TargetsCancer/testis antigen 1HLA Class I Histocompatibility Antigen, A-2 alpha Chain

Therapy Area/IndicationsHormone-Resistant Prostate NeoplasmsOvarian Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsYes

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesUnited Immunity Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesUnited Immunity Co Ltd

Active IndicationsN/A

Inactive IndicationsHormone-Resistant Prostate NeoplasmsOvarian Neoplasms

Other Information

ATC CodeN/A